RxDoctor Payments Data

Michele Ayotte

Nurse Practitioner · Apo, AENPI 1821532987

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,154 of the $1,747 with a category attached, or 66.1%. 17 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 50.5% of the total. Reporting peaked in 2024 at $1,109 and has fallen 98.1% since, to $21 in 2025.

$1,747in general payments, 2019–2025

Across 42 payments — averaging $41.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$882
  • Jazz Pharmaceuticals Inc.$205
  • Boston Scientific$121
  • Harmony Biosciences LLC$105
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$87
  • Avadel CNS Pharmaceuticals, LLC$74
  • plus $272 from 11 others

What the payments were for

  • Travel & lodging$46026%
  • Food & beverage$1,15466%
  • Education$1338%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nurse practitioner providers in AEto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$71,319
Medicare patients
393
Services billed
670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Methylphenidate Hcl14$170
Eszopiclone17$126
Clonazepam12$23
Zolpidem Tartrate22$21

Paid to pharmacies, not to this prescriber.

Other nurse practitioner in Apo

See the full list for AE

Where these figures come from

Is this you, or does something look wrong? →